Drug intelligence / Profile preview

APVO-437

Development stage: Preclinical
Lead developer: Aptevo Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

APVO-437 is an investigational bispecific T‑cell engaging antibody from Aptevo Therapeutics’ ADAPTIR platform that targets CD123 on malignant myeloid cells and CD3 on T cells to redirect T‑cell cytotoxicity against CD123‑expressing tumor cells, being explored primarily for acute myeloid leukemia and related CD123+ malignancies.[4][1] Preclinical evaluations reported antibody‑like serum half‑life in mice (up to ~12.5 days) and dose‑, target‑antigen‑, and effector:target‑dependent cytotoxicity in primary human AML specimens, with accompanying T‑cell activation and depletion of CD123+ populations.[4][1]

Targets

IL3RA (Interleukin 3 Receptor)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on APVO-437.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APVO-437.

Explore the full profile